Expression of Melan-A in Depigmented Skin of Vitiligo Patients
Downloads
Background: Vitiligo is an acquired and commonly found pigmentation disorder characterized by milky-white patches on the skin, hair, and mucosa due to melanocyte damage. The cause of vitiligo is still unclear. A study proves that cell-mediated immunity plays a role in the pathogenesis of vitiligo. Melan-A is a melanoma-related antigen that is recognized by autologous cytotoxic T cells and one of the critical markers for detecting melanocytes. Objective: To evaluate the expression of Melan-A in depigmented lesions of vitiligo patients. Methods: A descriptive study aimed to describe the expression of Melan-A in the depigmented skin of vitiligo patients at the Dermatovenerology Outpatient Clinic Cosmetic Division of Academic General Hospital Dr. Soetomo Surabaya. Eleven study subjects were selected through a sequence of selection. Results: Melan-A expression in the depigmented skin of vitiligo patients was lower than the average. This result was found in 6 (54.55%) out of 11 patients. Conclusion: Melan-A expressions on depigmented skins of vitiligo patients are generally below the average value; therefore, adequate intervention is needed to increase the Melan-A expression.
Birlea SA, Spritz RA, Norris DA. Vitiligo. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Leffel DJ, editors. Fitzpatrick's Dermatology General Medicine. 8th Ed. New York: McGraw Hill Co 2013. p.792-803.
Tarle RG, Mira MT, do Nascimento LM, de Castro CCS. Vitiligo - Part 1. An Bras Dermatol 2014;89(3): 461-70.
LeBoit PE. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol 2004; 26(2): 108-12.
Hutomo S. Penelitian retrospektif penderita vitiligo di divisi kosmetik medik URJ kesehatan kulit dan kelamin RSUD Dr. Soetomo Surabaya periode 2009-2011. Surabaya. 2012.
Ortonne JP. Pathogenesis and medical treatment of vitiligo. 2006; 19:46: 1-12.
Passeron T, Ortonne J. Generalized vitiligo. In: Picardo M, Taieb A, editors. Vitiligo. Berlin Heidelberg: Springer-Verlag; 2010. p:35-40.
Waterman EA, Kemp EH, Gakrodger DJ, Watson PF, Weetman AP. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin Exp Immunol 2002;129:527-32.
Abdel-Aal AM, Kasem MA, Abdel-Rahman AH. Evalution of the role of apoptosis in vitiligo: immunohistochemical expression of P53, Bcl-2 and MART-1 Antigens. Egypt J Hosp Med 2002; 8: 1-11.
Kubanov A, Proshutinskaia D, Volnukhin V, Katunina O, Abramova T. Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker. Acta Dermatovenerol APA 2016; 25:5-9.
Kholy MA. Immunohistochemical expression of melan A and its relation to expression of CXCR3 in vitiligo lesions. Al-Azhar Med J 2016; 45(4): 921-30.
Massi D. Histopathological and ultrastructural features of vitiligo. In: Lotti T, Hercogova (eds). Vitiligo Problems and Solution. New York 2004; 12: 160-72.
Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. Hindawi. 2011;1-3.
Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in vitiligo: An update on medical and surgical treatments. J Clin Aesthet Dermatol. 2017;10(1): 15-28.
Bishnoi A, Parsad D. A Clinical and molecular aspects of vitiligo treatments. Int J Mol Sci 2018; 19(5): 1509.
Parsad D. A New era of vitiligo research and treatment. J Cutan Aesthet Surg. 2013; 6: 63-4.
Rahman R, Hasija Y. Exploring vitiligo susceptibility and management: a brief review. Biomed Dermatol. 2018; 2:20.
Selvan BS, Thadeus J, Anandan H. Pattern of repigmentation in the treatment of vitiligo vulgaris with NBUVB Therapy. Int J Contemp Med Res. 2018; 5(5): E1-E3.
Bleuel R, Eberlein B. Therapeutic management of vitiligo. J Dtsch Dermatol Ges. 2018; 16: 1309-13.
Nai GA, Miot LBD, Miot HA, Marques MEA. Immunohistochemistry for early diagnosis of vitiligo. J Bras Patol Med Lab 2008; 44(5): 367-373.
Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening Jan, Das Pranab. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81(8): 1061.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
